45 Poplar Road
76 articles with CSL Limited
Novartis' canakinumab failed again in non-small cell lung cancer while Anixa Biosciences, Palisade Bio and Genexine kicked off new trials.
CSL advances its vision for a more sustainable future by setting new, tangible targets for carbon emissions reductions.
CSL Limited is pleased to announce it has now received all necessary regulatory clearances for the acquisition of Vifor Pharma AG announced on 14 December 2021.
CSL Limited yesterday announced an update regarding the Vifor Pharma AG acquisition.
Publication of provisional end result for Vifor Pharma tender offer: Participation rate of 94 percent
CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited, announced the provisional notice of the end result of its public tender offer to acquire all publicly held shares of Vifor Pharma Ltd. for USD 179.25 per share as indicated in the offer prospectus of 18 January 2022.
Publication of definitive Interim Result for Vifor Pharma tender offer: CSL Behring AG declares offer successful
CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited, announced the definitive notice of the Interim Result of its public tender offer to acquire all publicly held shares of Vifor Pharma Ltd.
Seqirus and U.S. Government Renew Multi-Year Agreement for Influenza Pandemic Preparedness and Response
Seqirus announced the renewal of a five-year agreement with the Biomedical Advanced Research and Development Authority, a division of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services.
Seqirus, a Business of CSL Limited, Announces New Facility Supporting Research & Development of Leading-Edge Influenza Vaccine Technology
Seqirus, a global leader in influenza prevention and a business of CSL Limited, announced an investment in a new Research and Development facility located in Waltham, Mass.
CSL Behring AG publishes Offer Prospectus on public tender offer for all publicly held shares of Vifor Pharma Ltd.
CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited, published the offer prospectus regarding its public tender offer for all publicly held registered shares of Vifor Pharma Ltd., a global specialty pharmaceutical company with leadership in Iron Deficiency, Nephrology & Cardio-Renal Therapies, as indicated in the pre-announcement of the public tender offer published by CSL Limited on 14 December 2021.
Global biotechnology leader CSL Limited and Vifor Pharma Ltd, a global specialty pharmaceutical company with leadership in iron deficiency, nephrology & cardio-renal therapies, announced that they have entered into a definitive agreement for CSL to acquire Vifor Pharma for an aggregate equity value for Vifor Pharma of US$ 11.7 / CHF 10.9 billion.
If successfully finalized, the transaction will give CSL access to Vifor’s pipeline of treatments for iron deficiency, kidney and cardio-renal diseases.
The deal, which could be worth as much as $12 billion USD, was also confirmed by CSL speaking to Reuters Monday morning.
Marked by recent announcements of new manufacturing sites, headquarters and job creations, the life science industry continues to thrive despite the COVID-19 pandemic.
Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced that the Company has entered into licensing agreements and strategic partnerships with Seqirus Pty Ltd, a subsidiary of CSL Limited, and AVIR Pharma Inc. for tirbanibulin.
As a devastating pandemic increased scientific collaboration globally, CSL was already ahead of the curve with teams spanning the continents, working together to advance lifesaving treatments and technologies.
Forbes magazine has named global biotechnology leader CSL Limited to its World's Best Employers 2020 list.
Thermo Fisher Scientific and CSL Enter Strategic Partnership to Provide Best-in-Class Pharma Services
Thermo Fisher Scientific Inc., the world leader in serving science, and global biotechnology company, CSL Limited announced they have entered into a strategic partnership to help meet the growing demand for biologic therapies while also accelerating CSL's broader manufacturing objectives.
Top 100 CEO rankings based on financial performance as well as environmental, social, and governance (ESG) ratings
Pharming categorically denies having had any involvement in the alleged abstraction of proprietary information by Dr Joseph Chiao from his former employer CSL
She will replace Gordon Naylor, who announced his retirement earlier this year.